Table 1.
Disease severity in critically ill patients and mortality: mortality rates of all subjects in the RECOVERY and ACTT-1 trials for COVID-19.
| Diseaseseverity in critically ill patients and mortality | |||||
|---|---|---|---|---|---|
| SOFAscore [15] | NEWS or NEWS2score [12] | mSOFA score [69] | |||
| Mean SOFA score | Mortality | Initial score | 30-day mortality | Initial score | 30-day mortality |
| 0–1 | 1% | 1–4 | 5.5% | 0–7 | 4% |
| 1.1–2.0 | 5% | 5–6 | 11.3% | 8–11 | 31% |
| 2.1–3.0 | 16% | 7–8 | 13.3% | >11 | 58% |
| 3.1–4.0 | 13% | 9–20 | 27.6% | ||
| 4.1–5.0 | 19% | ||||
| >5.1 | 27% | ||||
| The following four hypothetical patients who are on the same 4 L of oxygen on nasal canula and have the same pre-existing baseline co-morbidities, and their risk of death is based on disease severity. | |||||
| NEWSscore [12] | |||||
| Score range | 30-day mortality | |
| Patient 1 | 1–4 | 5.5% |
| Patient 2 | 5–6 | 11.3% |
| Patient 3 | 7–8 | 13.3% |
| Patient 4 | 9–20 | 27.6% |
| Mortality rate (all trial subjects) in the COVID-19 randomised trials | ||
| Mortality rate | Chances for randomisation sampling errors | |
| Recovery–Dexamethasone (n = 6425) 28-day mortality [5] | 24.8% | Very high |
| Recovery–Hydroxychloroquine (n = 4716) 28-day mortality [6] | 25.6% | Very high |
| ACTT-1 remdesivir (n = 1059) No. of deaths at 14 days [4] | 8.2% | Very high |
COVID, coronavirus disease 2019; SOFA, Sequential Organ Failure Assessment; NEWS, National Early Warning Score; mSOFA, modified Sequential Organ Failure Assessment.